Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

US Alcohol Consumption Holds at Historic Low as Majority of Americans Now Say Drinking Is Bad for Health

by Team Lumida
August 20, 2026
in Health and Longevity
Reading Time: 4 mins read
A A
0
clear drinking glass with ice cubes

Photo by Vinicius "amnx" Amano on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The share of Americans who say they consume alcohol on occasion held at 54% in 2026, matching the historic low set last year and halting three consecutive years of annual declines, according to a Gallup poll of 1,200 adults conducted July 1-19 — a potential stabilization signal for an alcohol industry that has seen sustained sales declines and significant stock price deterioration at Brown-Forman, Molson Coors, and Boston Beer.
  • While the drinking participation rate stabilized, health attitudes continued to shift: 51% of Americans now say alcohol is bad for their wellness — a figure that remained below 30% for nearly two decades before 2020, when awareness of alcohol’s health risks began accelerating rapidly — and only 13% self-report that they drink too much, the lowest proportion on record, suggesting that the cultural normalization of moderate or zero drinking is deepening even among those who still consume.
  • The average number of drinks per week inched up to 3.2 from 2.8 the previous year among those who do drink, suggesting that the population that continues to consume alcohol may be drinking slightly more — a pattern consistent with market consolidation around committed drinkers as casual consumers exit the category, which could concentrate revenue in fewer but more loyal customers while the overall addressable market contracts.
  • The decline in alcohol consumption is broad-based across gender, race, age, and religion — and notably bipartisan, with both Republicans and independents reporting reduced drinking over the past three years while Democrats have held steady — suggesting this is a structural cultural shift rather than a demographic or political niche phenomenon, driven by a combination of GLP-1 drug use reducing appetite for alcohol, rising health awareness, THC beverage alternatives, and squeezed household budgets reducing discretionary spending.

What Happened?

Gallup released its annual alcohol consumption survey — which has tracked American drinking behavior since 1939 — showing that the share of adults who drink on occasion stabilized at 54% in 2026, matching last year’s historic low after three consecutive annual declines from approximately 62% in 2023. The survey, conducted July 1-19 among 1,200 adults by phone, found simultaneous evidence of both stabilization and continued negative structural trends: the participation rate stopped falling, but the share of Americans who believe alcohol is bad for their health rose to 51% — a level that would have been unimaginable as recently as 2019, when the figure was under 30%. The stabilization at 54% is being interpreted as tentative good news by an alcohol industry that has been struggling to absorb declining volume and has seen sustained stock price declines at major producers including Brown-Forman, Molson Coors, and Boston Beer.

Why It Matters?

The alcohol industry’s structural demand challenge is unlike the cyclical downturns it has navigated in previous decades. The current decline in consumption is driven by converging forces that reinforce each other: a rapid increase in health awareness about alcohol’s risks following the pandemic and updated medical guidance; the proliferation of non-alcoholic and THC-infused alternatives that provide social drinking substitutes; squeezed household budgets that are reducing discretionary spending across non-essential categories; and, increasingly, the growing prevalence of GLP-1 weight-loss drugs like Ozempic and Wegovy, which research suggests meaningfully reduce cravings for alcohol and other rewards. Unlike previous health trend-driven demand shifts that primarily affected specific product categories (e.g., the decline in sweet wines or full-calorie beer), the current shift is category-wide and demographically broad. The bipartisan nature of the decline — Republicans and independents cutting back while Democrats hold steady — suggests this is not a cultural trend confined to health-conscious liberal demographics but a genuinely widespread behavioral shift.

What’s Next?

The stabilization of the drinking participation rate at 54% may offer the alcohol industry a respite from sustained volume declines, but the longer-term strategic question is whether the industry can recapture lost consumers or must simply adjust its business model to serve a structurally smaller and more value-oriented customer base. The category faces continued headwinds: GLP-1 drug adoption is still in early innings, with millions of new prescriptions written monthly and the addressable population expanding as Novo Nordisk tests lower-dose oral formulations for overweight rather than obese patients; non-alcoholic beer, wine, and spirit alternatives are rapidly improving in quality and growing in retail presence; and the generation entering legal drinking age (Gen Z) has shown persistently lower alcohol consumption rates than prior cohorts. Companies like Brown-Forman and Molson Coors will need to decide how aggressively to invest in premium-priced lower-volume strategies versus pursuing the non-alcoholic and functional beverage adjacencies where category growth is currently concentrated.

Source: Bloomberg

Previous Post

Trump Pauses 50% Tariff on Certain Canadian Goods for 3 Days, Declaring “We Have a Deal”

Next Post

JPMorgan Warns Bessent’s Bond Buybacks Lack Credibility — and Could Make the Yield Problem Worse Over Time

Recommended For You

AI-Discovered Drug Reverses Biological Aging by Up to 6 Years in Mid-Stage Trial, Nature Biotechnology Study Finds

by Team Lumida
1 day ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Insilico Medicine's rentosertib — an AI-designed lung disease drug — reduced biological age by up to six years in a 42-patient mid-stage trial, per a Nature Biotechnology study,...

Read more

Oura Faces Class-Action Over Sleep Data Accuracy — And the Whole Wearables Industry Is Watching

by Team Lumida
2 days ago
person clicking Apple Watch smartwatch

A proposed class-action lawsuit alleges Oura's ring failed to reliably track sleep — raising questions about the gap between wearable health trackers' marketing promises and what their data...

Read more

Employer Healthcare Costs Projected to Rise 9.5% in 2027 — Fourth Consecutive Year of Near-Double-Digit Increases

by Team Lumida
1 week ago
doctor holding red stethoscope

Average healthcare costs are projected to reach more than $19,000 per employee in 2027, a 9.5% year-over-year increase, according to Aon. This marks the fourth consecutive year of...

Read more

Big Food’s GLP-1 Reckoning: Conagra, Kraft, and Packaged-Food Giants Reformulate for the Not-So-Hungry

by Team Lumida
3 weeks ago
pasta with red sauce on white ceramic round plate

As GLP-1 weight-loss drugs suppress appetite across millions of households, packaged-food companies are retooling recipes, portion sizes, and sensory profiles to win over consumers who eat less but...

Read more

Novo Nordisk Tests Low-Dose Wegovy Pills as Most Patients Already Stick to Smallest Doses

by Team Lumida
3 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has launched a 450-person trial to determine the minimum effective dose of its oral Wegovy pill — a clinically significant shift given that more than two-thirds...

Read more

4 in 5 Americans Say Healthcare Costs Are the Nation’s Top Health Problem — and Nobody Agrees on Who Should Fix It

by Team Lumida
3 weeks ago
doctor holding red stethoscope

A Commonwealth Fund survey of 25,873 adults finds near-universal alarm over health insurance premiums and out-of-pocket costs, even as ACA marketplace premiums surge 58% in 2026 and nearly...

Read more

Wealthy, Healthy, and Ready to Spend: Baby Boomers Are Driving a Global Travel Boom the Industry Is Racing to Serve

by Team Lumida
3 weeks ago
couple kissing on the road during daytime

Baby boomers — flush with retirement savings and in better health than previous generations — are fueling a high-end travel surge, with the industry responding with private-plane tours,...

Read more

385 Million Patient Records Breached and Counting — DentaQuest’s 15M-Person Hack Leads a New Wave of Healthcare Cybersecurity Disasters

by Team Lumida
4 weeks ago
person sitting while using laptop computer and green stethoscope near

The updated Healthcare Dive breach tracker reveals a sector in crisis: DentaQuest's 15M breach in 2026, Conduent's 62M in 2025, and Change Healthcare's record 192.7M in 2024.

Read more

Healthcare Stocks Are Now an Implicit AI Short — Semiconductors and Pharma Have Flipped to Negative Correlation

by Team Lumida
4 weeks ago
turned on monitoring screen

A structural shift is underway in equity markets: the VanEck Semiconductor ETF and the State Street Health Care ETF have moved into negative correlation, meaning healthcare has effectively...

Read more

Patients Are Using AI to Interpret Their Medical Test Results Before Seeing Doctors — And Doctors Are Struggling to Untangle the Errors

by Team Lumida
1 month ago
doctor holding red stethoscope

Roughly a third of American adults now consult AI for health advice, and the majority view test results online before speaking with a doctor — a trend accelerated...

Read more
Next Post
Tax-Loss Harvesting Surge: JPMorgan’s $15 Billion Windfall

JPMorgan Warns Bessent's Bond Buybacks Lack Credibility — and Could Make the Yield Problem Worse Over Time

Dollar’s Decline: What Traders Need to Know About Fed Rate Cuts

The Dollar Is Becoming the Biggest Loser From Bessent's Bond Buybacks, Strategists Warn

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Trump Pushes for Greenland Acquisition, Exploring Business Deals and Military Presence

Trump Media Posts $405 Million Loss Driven by Bitcoin Holdings Bought at Peak

May 11, 2026
Circle Insiders Rush to Cash Out $1.4 Billion After 349% Stock Surge Since IPO

Circle Insiders Rush to Cash Out $1.4 Billion After 349% Stock Surge Since IPO

August 15, 2025
Circle Surges 14% on $222 Million ARC Blockchain Pre-Sale, Even as Revenue Misses

Circle Surges 14% on $222 Million ARC Blockchain Pre-Sale, Even as Revenue Misses

May 12, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018